Go to content
UR Home

Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial

Pal, Sumanta K ; Somford, Diederik M ; Grivas, Petros ; Sridhar, Srikala S ; Gupta, Shilpa ; Bellmunt, Joaquim ; Sonpavde, Guru ; Fleming, Mark T ; Lerner, Seth P ; Loriot, Yohann ; Hoffman-Censits, Jean ; Valderrama, Begoña P ; Andresen, Corina ; Schnabel, Marco J ; Cole, Suzanne ; Daneshmand, Siamak



Abstract

PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include postsurgical high-risk muscle-invasive upper tract urothelial cancer (85% of patients) or urothelial bladder cancer (15%), susceptible FGFR3 alterations (activating mutations, gene fusions or ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons